← SynDRA
HALOPEMIDE
SynDRA canonical compound SYN0007803 — structure-anchored drug synonym record
| Clinical phase | Phase 2 |
|---|
| Primary target(s) | PLD1 | PLD2 |
|---|
| Mechanism of action | phospholipase inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- phospholipase inhibitor
- PLD1 INHIBITOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- DRD2
- ADGRF1
- GLP1R
- S1PR1
- NTHL1
- NEIL2
- NEIL1
- GPR35
- GPR119
- FPR2
- ADRA2A
- FFAR4
- CX3CR1
- C5AR1
- APLNR
- AGTR1
- ADRB2
- TDG
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Cross-references
Synonyms
- Halopemida
- NSC-354856
- R 34,301
- R-34301
- UNII-65Q28TV0ZY
- MLS003171133
- 65Q28TV0ZY
- CHEMBL245621
- R 34301
- N-(2-(4-(5-Chloro-2-oxo-1-benzimidazolinyl)piperidino)ethyl)-p-fluorobenzamide
- Halopemidum
- Halopemide [USAN:INN]
- Halopemidum [INN-Latin]
- Halopemida [INN-Spanish]
- C21H22ClFN4O2
- N-[2-[4-(5-Chloro-2-oxo-1-benzimidazolinyl)piperidino]ethyl]-p-fluorobenzamide
- Halopemide, 8
- NSC 354856
- Halopemide (USAN/INN)
- AC1L23CG
- MLS006012046
- cid_65490
- SCHEMBL121267
- Halopemide, >
- CTK8G0128
- AOB5520
- RefChem:783369
- DTXCID70131052
- NSC354856
- Halopemide?
- HALOPEMIDE [INN]
- HALOPEMIDE [USAN]
- orb1308234
- Halopemide, >=98% (HPLC)
- NBHPRWLFLUBAIE-UHFFFAOYSA-N
- GLXC-06647
- HMS3648G20
Look up HALOPEMIDE in the interactive SynDRA portal →